Synthon B.v.

Luis Nogueiras Nieto

Lisardo Alvarez Fernandez

Rohit Kumar

Jose Velada Calzada

Marta Vivancos Martinez

Deepak Murpani

Rolf Keltjens

Raymond Westheim

Jacobus Theodorus Henricus Van Eupen

Petr Mitas

Sara Fradera Gelabert

Bohumil Dymacek

Sonia Garcia Jimenez

Katerina Jelinkova

Jacobus Theodorus Henricus Eupen Van

Lisardo ÁLvarez FERNÁNDEZ

José Velada Calzada

The present invention relates to a film-coated swallowable tablet comprising eltrombopag bis(monoethanolamine) and pharmaceutically acceptable excipients comprising calcium silicate as diluent. The invention further relates to the use of said tablet as a medicament, particularly in the treatment of immune thrombocytopenia (ITP), thrombocytopenia in patients with chronic hepatitis C virus (HCV) and severe aplastic anaemia (SAA).

Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)

The present invention relates to lenvatinib besylate, its crystalline forms and processes for making them. Furthermore, to a pharmaceutical composition comprising a therapeutically effective dose of lenvatinib besylate.

Crystalline forms and processes of lenvatinib besylate

The present invention relates to a pharmaceutical composition comprising a therapeutically effective dose of Lenvatinib mesylate having sodium wherein the weight ratio of Lenvatinib mesylate to sodium carbonates ranges from 1:1.5 to 1:5.

Pharmaceutical composition comprising Lenvatinib mesylate

The present invention relates to a pharmaceutical composition comprising pomalidomide, maltodextrin and a filler, wherein the weight ratio of maltodextrin to filler ranges from 1:1 to 1:2. The invention further relates to the use of said pharmaceutical composition as medicament in the treatment of multiple myeloma.

Pharmaceutical composition comprising pomalidomide

The present invention relates to a tablet composition comprising ibrutinib and one or more pharmaceutically acceptable excipients, characterized in that: The invention further relates to the use of said composition as a medicament, particularly in the treatment of chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL) and Waldenstr&#xf6;m's macroglobulinaemia (WM).

Pharmaceutical composition comprising ibrutinib

The present invention relates to a pharmaceutical composition comprising a physical mixture of sacubitril sodium and valsartan disodium, wherein the X-ray powder diffraction pattern of valsartan disodium comprises characteristic peaks at the following 2 theta (&#xb1;0.2) angles: 4.70&#xb0;, 9.29&#xb0;, 22.34&#xb0;, measured using a Cu K&#x3b1; radiation. The invention further relates to the use of said pharmaceutical composition as medicament in the treatment of heart failure.

Pharmaceutical composition comprising sacubitril and valsartan

The present invention relates to a pharmaceutical composition comprising an amorphous adsorbate of lenalidomide, or a pharmaceutically acceptable salt thereof, on a porous carrier and one or more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of multiple myeloma and myelodysplastic syndromes.

Pharmaceutical composition comprising amorphous lenalidomide

The present invention relates to a pharmaceutical composition comprising an inclusion complex of amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, in non-substituted &#x3b2;-cyclodextrin and one or more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodysplastic syndromes.

Growing community of inventors

Sant Boi de Llobregat, Spain

Luis Nogueiras Nieto